# A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

> **NCT07043634** · PHASE3 · COMPLETED · sponsor: **Sarfez Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Bioavailability Heathy Volunteers

## Interventions

- **COMBINATION_PRODUCT:** FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
- **COMBINATION_PRODUCT:** FDC (24 mg ER torsemide and 30 mg Spironolactone) with food

## Key facts

- **NCT ID:** NCT07043634
- **Lead sponsor:** Sarfez Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043634, "A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07043634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*